RGEN PE Ratio & Valuation,Is RGEN Overvalued

RGEN Relative Valuation

RGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RGEN is overvalued; if below, it's undervalued.

Historical Valuation

Repligen Corp (RGEN) is now in the Fair zone, suggesting that its current forward PE ratio of 81.65 is considered Fairly compared with the five-year average of 83.98. The fair price of Repligen Corp (RGEN) is between 121.54 to 182.54 according to relative valuation methord.

Relative Value

Fair Zone

121.54-182.54

Current Price：157.39

Fair

81.65

56.42

EV/EBITDA

Repligen Corp. (RGEN) has a current EV/EBITDA of 56.42. The 5-year average EV/EBITDA is 56.69. The thresholds are as follows: Strongly Undervalued below 27.92, Undervalued between 27.92 and 42.31, Fairly Valued between 71.08 and 42.31, Overvalued between 71.08 and 85.46, and Strongly Overvalued above 85.46. The current Forward EV/EBITDA of 56.42 falls within the Historic Trend Line -Fairly Valued range.

75.80

EV/EBIT

Repligen Corp. (RGEN) has a current EV/EBIT of 75.80. The 5-year average EV/EBIT is 71.49. The thresholds are as follows: Strongly Undervalued below 26.33, Undervalued between 26.33 and 48.91, Fairly Valued between 94.07 and 48.91, Overvalued between 94.07 and 116.65, and Strongly Overvalued above 116.65. The current Forward EV/EBIT of 75.80 falls within the Historic Trend Line -Fairly Valued range.

11.11

Repligen Corp. (RGEN) has a current PS of 11.11. The 5-year average PS is 13.99. The thresholds are as follows: Strongly Undervalued below 7.33, Undervalued between 7.33 and 10.66, Fairly Valued between 17.32 and 10.66, Overvalued between 17.32 and 20.65, and Strongly Overvalued above 20.65. The current Forward PS of 11.11 falls within the Historic Trend Line -Fairly Valued range.

59.62

P/OCF

Repligen Corp. (RGEN) has a current P/OCF of 59.62. The 5-year average P/OCF is 61.19. The thresholds are as follows: Strongly Undervalued below 33.09, Undervalued between 33.09 and 47.14, Fairly Valued between 75.24 and 47.14, Overvalued between 75.24 and 89.30, and Strongly Overvalued above 89.30. The current Forward P/OCF of 59.62 falls within the Historic Trend Line -Fairly Valued range.

71.10

P/FCF

Repligen Corp. (RGEN) has a current P/FCF of 71.10. The 5-year average P/FCF is 99.58. The thresholds are as follows: Strongly Undervalued below 35.30, Undervalued between 35.30 and 67.44, Fairly Valued between 131.71 and 67.44, Overvalued between 131.71 and 163.85, and Strongly Overvalued above 163.85. The current Forward P/FCF of 71.10 falls within the Historic Trend Line -Fairly Valued range.

Repligen Corp (RGEN) has a current Price-to-Book (P/B) ratio of 4.25. Compared to its 3-year average P/B ratio of 4.34 , the current P/B ratio is approximately -2.02% higher. Relative to its 5-year average P/B ratio of 5.38, the current P/B ratio is about -21.01% higher. Repligen Corp (RGEN) has a Forward Free Cash Flow (FCF) yield of approximately 1.24%. Compared to its 3-year average FCF yield of 1.25%, the current FCF yield is approximately -0.80% lower. Relative to its 5-year average FCF yield of 0.91% , the current FCF yield is about 36.19% lower.

4.25

P/B

Median3y

4.34

Median5y

5.38

1.24

FCF Yield

Median3y

1.25

Median5y

0.91

Competitors Valuation Multiple

The average P/S ratio for RGEN's competitors is 238.63, providing a benchmark for relative valuation. Repligen Corp Corp (RGEN) exhibits a P/S ratio of 11.11, which is -95.34% above the industry average. Given its robust revenue growth of 21.91%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of RGEN increased by 9.34% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 298.92 to 6.18K.

The secondary factor is the Revenue Growth, contributed 21.91%to the performance.

Overall, the performance of RGEN in the past 1 year is driven by P/E Change. Which is more unsustainable.

21.91%

154.87M → 188.81M

Revenue Growth

-1980.95%

-0.42 → 7.90

Margin Expansion

1968.38%

298.92 → 6.18K

P/E Change

9.34%

143.94 → 157.39

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Repligen Corp (RGEN) currently overvalued or undervalued?

What is Repligen Corp (RGEN) fair value?

RGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Repligen Corp (RGEN) is between 121.54 to 182.54 according to relative valuation methord.

How does RGEN's valuation metrics compare to the industry average?

What is the current P/B ratio for Repligen Corp (RGEN) as of Dec 15 2025?

As of Dec 15 2025, Repligen Corp (RGEN) has a P/B ratio of 4.25. This indicates that the market values RGEN at 4.25 times its book value.

What is the current FCF Yield for Repligen Corp (RGEN) as of Dec 15 2025?

As of Dec 15 2025, Repligen Corp (RGEN) has a FCF Yield of 1.24%. This means that for every dollar of Repligen Corp’s market capitalization, the company generates 1.24 cents in free cash flow.

What is the current Forward P/E ratio for Repligen Corp (RGEN) as of Dec 15 2025?

As of Dec 15 2025, Repligen Corp (RGEN) has a Forward P/E ratio of 81.65. This means the market is willing to pay $81.65 for every dollar of Repligen Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Repligen Corp (RGEN) as of Dec 15 2025?

As of Dec 15 2025, Repligen Corp (RGEN) has a Forward P/S ratio of 11.11. This means the market is valuing RGEN at $11.11 for every dollar of expected revenue over the next 12 months.

RGEN Valuation